Rani Therapeutics Holdings, Inc. (RANI) Stock Price & Analysis
Rani Therapeutics Holdings, Inc. (RANI) closed at USD 0.68 on Thursday, October 15, 2026, up 1.46% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.67; the Oct 15, 2026 session ranged USD 0.65–0.69 on volume of 438,439 shares. Market capitalization is $95.55M, with a 52-week range of USD 0.61–3.87 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RANI.md
Key facts (RANI)
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 7.2 (range 5–11).
- Total return with dividends: 1Y +44.4% vs S&P 500 +18.1%; 5Y -96.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.05, revenue estimate $1.3M.
Analysts (RANI)
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 7.2 (low 5, high 11).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-21 | HC Wainwright & Co. | Reiterated | Buy | $11 |
| 2026-08-18 | Chardan Capital | Initiated | Buy | $6 |
Total return (dividends reinvested) (RANI)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +44.4% | -96.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +44.6% | -48.9% |
| Volatility (annualized) | 165.2% | 99.7% |
| Max drawdown | -77.8% (Oct 2025→Jul 2026) | -98.8% (Nov 2021→Jul 2025) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 0.68 |
|---|---|
| Change | ▲ 1.46% (up) |
| Previous Close | USD 0.67 |
| Open | USD 0.66 |
| Day Range | USD 0.65 – 0.69 |
| 52-Week Range | USD 0.61 – 3.87 |
| Volume | 438,439 shares |
| Market Cap | $95.55M |
| Exchange | NGM |
Technical Analysis (RANI)
Nexqual's technical model rates RANI "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.26 (neutral) |
| vs SMA50 | Below (USD 0.81) |
| MACD | -0.03 (negative) |
Analyst Ratings (RANI)
Wall Street analysts rate RANI "Buy" based on 5 analysts, with a mean price target of USD 7.2 (range USD 5–11), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 7.2 |
| High Target | USD 11 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (RANI)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.05 |
| Revenue Estimate | $1.28M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.04 vs est -0.05 ▲ beat |
| 2026-03-31 | USD -0.04 vs est -0.04 ▲ beat |
| 2025-12-31 | USD -0.07 vs est -0.07 ▼ miss |
| 2025-09-30 | USD -0.12 vs est -0.12 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (RANI)
| Total Revenue | $4.88M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -516.86% |
| Profit Margin | +0.00% |
| ROE | -172.15% |
| Debt / Equity | 0.07 |
| Current Ratio | 5.31 |
| Total Cash | $53.39M |
| Total Debt | $3.55M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (RANI)
Nexqual rates Rani Therapeutics Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Strong — Revenue +59% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $53M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$20M (TTM) |
| Efficiency | Critical — ROE -172%, ROA -53.0% |
Ownership (RANI)
| Insider Ownership | +4.91% |
|---|---|
| Institutional Ownership | +46.81% |
| Shares Outstanding | 115.42M |
| Float | 82.32M |
| Short % of Float | +6.45% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (RANI)
Rani Therapeutics Holdings, Inc. is led by Talat Imran (age 43), CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO & Director | Talat Imran (age 43) |
|---|---|
| Executive Chairman | Mir A. Imran (age 69) |
| Chief Financial Officer | Nicholas Maestas (age 45) |
| Chief Scientific Officer | Mir Hashim (age 65) |
| Senior Vice President of People & Administrative Services | Bella Vazquez |
Major Backers & Investors (RANI)
Notable institutional backers of Rani Therapeutics Holdings, Inc. include Samsara BioCapital, LLC, RA Capital Management, L.P., AWM Investment Company, Inc., according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Samsara BioCapital, LLC | 8.98% |
| RA Capital Management, L.P. | 7.36% |
| AWM Investment Company, Inc. | 6.5% |
| SymBiosis Capital Partners, LLC | 3.18% |
| Longaeva Partners L.P. | 2.02% |
| Polar Asset Management Partners Inc. | 2.01% |
| Siren, L.L.C. | 1.73% |
| Heights Capital Management, Inc | 0.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.9% |
| Geode Capital | 0.77% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt